TY - JOUR
T1 - Mild cognitive impairment and mild dementia
T2 - A clinical perspective
AU - Knopman, David S.
AU - Petersen, Ronald C.
N1 - Funding Information:
Potential Competing Interests: Dr Knopman serves as Deputy Editor for Neurology; serves on data safety monitoring boards for Lundbeck Pharmaceuticals and for the Dominantly Inherited Alzheimer’s Disease Treatment Unit; has served on a data safety monitoring board for Eli Lilly and Company; served as a consultant to Tau Rx Therapeutic Ltd; in the past 2 years; and receives research support from the National Institutes of Health. Dr Petersen serves on data monitoring committees for Pfizer, Inc, and Janssen Alzheimer Immunotherapy; is a consultant for Elan Pharmaceuticals, Inc, Roche Inc, and Merck & Co, Inc; receives publishing royalties from Oxford University Press; and receives research support from the National Institutes of Health/National Institute on Aging.
Funding Information:
Grant Support: This work was supported in part by grants U01 AG06786 ( Mayo Clinic Study of Aging ) and P50 AG016574 ( Mayo Alzheimer Center ) and by funds from the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program.
Publisher Copyright:
© 2014 Mayo Foundation for Medical Education and Research.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Mild cognitive impairment and mild dementia are common problems in the elderly. Primary care physicians are the first point of contact for most patients with these disorders and should be familiar with their diagnosis, prognosis, and management. Both mild cognitive impairment and mild dementia are characterized by objective evidence of cognitive impairment. The main distinctions between mild cognitive impairment and mild dementia are that in the latter, more than one cognitive domain is invariably involved and substantial interference with daily life is evident. The diagnosis of mild cognitive impairment and mild dementia is based mainly on the history and cognitive examination. The prognosis for mild cognitive impairment and mild dementia is an important motivation for diagnosis because in both, there is a heightened risk for further cognitive decline. The etiology of mild cognitive impairment and mild dementia can often be established through the clinical examination, although imaging and other laboratory tests may also contribute. Although Alzheimer disease is the most common cause of both, cerebrovascular disease and Lewy body disease make important contributions. Pharmacological treatments are of modest value in mild dementia due to Alzheimer disease, and there are no approved pharmacological treatments for mild cognitive impairment of any etiology. Nonetheless, new-onset cognitive impairment is a worrisome symptom to patients and families that demands answers and advice. If a patient is having difficulties managing medications, finances, or transportation independently, diagnosis and intervention are necessary to ensure the health and safety of the patient.
AB - Mild cognitive impairment and mild dementia are common problems in the elderly. Primary care physicians are the first point of contact for most patients with these disorders and should be familiar with their diagnosis, prognosis, and management. Both mild cognitive impairment and mild dementia are characterized by objective evidence of cognitive impairment. The main distinctions between mild cognitive impairment and mild dementia are that in the latter, more than one cognitive domain is invariably involved and substantial interference with daily life is evident. The diagnosis of mild cognitive impairment and mild dementia is based mainly on the history and cognitive examination. The prognosis for mild cognitive impairment and mild dementia is an important motivation for diagnosis because in both, there is a heightened risk for further cognitive decline. The etiology of mild cognitive impairment and mild dementia can often be established through the clinical examination, although imaging and other laboratory tests may also contribute. Although Alzheimer disease is the most common cause of both, cerebrovascular disease and Lewy body disease make important contributions. Pharmacological treatments are of modest value in mild dementia due to Alzheimer disease, and there are no approved pharmacological treatments for mild cognitive impairment of any etiology. Nonetheless, new-onset cognitive impairment is a worrisome symptom to patients and families that demands answers and advice. If a patient is having difficulties managing medications, finances, or transportation independently, diagnosis and intervention are necessary to ensure the health and safety of the patient.
UR - http://www.scopus.com/inward/record.url?scp=84908093671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908093671&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2014.06.019
DO - 10.1016/j.mayocp.2014.06.019
M3 - Review article
C2 - 25282431
AN - SCOPUS:84908093671
SN - 0025-6196
VL - 89
SP - 1452
EP - 1459
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 10
ER -